1033810-14-8

Basic information

• Product Name: BenzenaMine, 3-chloro-4-(1H-indazol-4-yloxy)-
• Synonyms: BenzenaMine, 3-chloro-4-(1H-indazol-4-yloxy)-;3-Chloro-4-(1H-indazol-4-yloxy)aniline;4-((1H-Indazol-4-yl)oxy)-3-chloroaniline
• CAS NO: 1033810-14-8
• Molecular Formula: C₁₃H₁₀ClN₃O
• Molecular Weight: 259.691
• Mol File: 1033810-14-8.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: BenzenaMine, 3-chloro-4-(1H-indazol-4-yloxy)-(CAS DataBase Reference)
• NIST Chemistry Reference: BenzenaMine, 3-chloro-4-(1H-indazol-4-yloxy)-(1033810-14-8)
• EPA Substance Registry System: BenzenaMine, 3-chloro-4-(1H-indazol-4-yloxy)-(1033810-14-8)

Safety Data

• Hazardous Substances Data: 1033810-14-8(Hazardous Substances Data)

Usage

General Description

Benzenamine, 3-chloro-4-(1H-indazol-4-yloxy)-, also known as AG-120, is a chemical compound that belongs to the class of indazole derivatives. It is a potent inhibitor of isocitrate dehydrogenase 1 (IDH1), an enzyme that plays a role in cellular metabolism. AG-120 has been studied for its potential use in the treatment of cancers harboring IDH1 mutations, such as acute myeloid leukemia and other solid tumors. Its mechanism of action involves blocking the mutant IDH1 enzyme, which in turn inhibits the production of 2-hydroxyglutarate, a metabolite that contributes to tumorigenesis. AG-120 has shown promising results in preclinical and clinical studies, and it continues to be investigated for its therapeutic potential in cancer treatment.

Upstream product

• 81382-45-8 4-hydroxyindazole 
• 41748-71-4 4-aminoindazole 

Relevant articles and documents

Design and synthesis of pyrrolo[3,2- d ]pyrimidine human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors: Exploration of novel back-pocket binders

To develop novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) kinase inhibitors, we explored pyrrolo[3,2-d]pyrimidine derivatives bearing bicyclic fused rings designed to fit the back pocket of the HER2/EGFR proteins. Among them, the 1,2-benzisothiazole (42m) ring was selected as a suitable back pocket binder because of its potent HER2/EGFR binding and cell growth inhibitory (GI) activities and pseudoirreversibility (PI) profile as well as good bioavailability (BA). Ultimately, we arrived at our preclinical candidate 51m by optimization of the N-5 side chain to improve CYP inhibition and metabolic stability profiles without a loss of potency (HER2/EGFR inhibitory activity, IC50, 0.98/2.5 nM; and GI activity BT-474 cells, GI50, 2.0 nM). Reflecting the strong in vitro activities, 51m exhibited potent tumor regressive efficacy against both HER2- and EGFR-overexpressing tumor (4-1ST and CAL27) xenograft models in mice at oral doses of 50 mg/kg and 100 mg/kg.